MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) by 22.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 192,563 shares of the company’s stock after purchasing an additional 35,821 shares during the quarter. Geode Capital Management LLC’s holdings in MAIA Biotechnology were worth $541,000 at the end of the most recent quarter.

Separately, XTX Topco Ltd purchased a new stake in shares of MAIA Biotechnology in the 3rd quarter worth about $31,000. 5.65% of the stock is currently owned by institutional investors.

MAIA Biotechnology Stock Performance

MAIA Biotechnology stock opened at $2.12 on Friday. MAIA Biotechnology, Inc. has a 52 week low of $0.99 and a 52 week high of $5.99. The stock has a market capitalization of $53.70 million, a P/E ratio of -1.54 and a beta of 0.14.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.21. Analysts forecast that MAIA Biotechnology, Inc. will post -1.3 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Cristian Luput bought 22,133 shares of MAIA Biotechnology stock in a transaction on Friday, November 1st. The shares were bought at an average cost of $2.51 per share, for a total transaction of $55,553.83. Following the acquisition, the director now owns 389,483 shares in the company, valued at approximately $977,602.33. This trade represents a 6.03 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Stan Smith bought 25,000 shares of MAIA Biotechnology stock in a transaction on Friday, December 13th. The stock was purchased at an average price of $1.87 per share, for a total transaction of $46,750.00. Following the completion of the acquisition, the director now owns 1,130,060 shares in the company, valued at $2,113,212.20. This represents a 2.26 % increase in their position. The disclosure for this purchase can be found here. Insiders own 36.98% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.